Skip to main content

Rhabdomyolysis

0
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Baxter International
1 program
septeXN/A
Vantive
VantiveIL - Deerfield
1 program
septeXN/A1 trial
Active Trials
NCT01467180Completed16Est. May 2014
Baxter
BaxterCosta Rica - Cartago
1 program
septeXN/A
CytoSorbents
CytoSorbentsPRINCETON, NJ
1 program
CytoSorb DevicePHASE_21 trial
Active Trials
NCT02111018Withdrawn0

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CytoSorbentsCytoSorb Device
VantivesepteX

Clinical Trials (2)

Total enrollment: 16 patients across 2 trials

Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis

Start: Mar 20140
Phase 2Withdrawn

Myoglobin Removal by High Cut-off CVVHD

Start: Nov 2011Est. completion: May 201416 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.